

In the Office Action, the Examiner required restriction under 35 U.S.C. §121 to one of the following inventions:

- Group I: Claim 1, drawn to an antibody which binds to PSCA;
- Group II: Claims 53-56 and 73, drawn to a method for inducing an immune response in a subject having a cancer; and
- Group III: Claims 57-72, drawn to a PSCA protein.

Applicants hereby elect the invention of Group II, with traverse, for prosecution at this time. With the amendments to the claims, Applicants respectfully submit that all pending claims, *i.e.*, claims 53-56 and 58-73, fall within the invention of Group II drawn to methods for inducing an immune response in a subject having a cancer. Accordingly, with the cancellation of claims 1 and 57 and the amendments to claims 58-72, the restriction requirement is rendered moot.

Thus, claims 53-56 and 58-73 should properly be examined together and Applicants respectfully request that in view of the amendments to the claims, the Examiner reconsider and withdraw the restriction requirement.

Applicant: Robert E. Reiter et al.


U.S. Serial No.: 09/854,811

Filed: May 14, 2001

Page 5

No fee is deemed necessary in connection with the filing of this Amendment. If any fee is necessary, the Patent Office is authorized to charge any additional fee to Deposit Account No. 50-0306.

Respectfully submitted,



Sarah B. Adriano
Registration No. 34,470
Stephanie Hsieh
Registration No. 38,497
Attorneys for Applicants
Mandel & Adriano
55 S. Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801
Customer No.: 26,941



VERSION WITH MARKINGS
TO SHOW CHANGES MADE IN CLAIMS

In the claims:

Please cancel claims 1 and 57, without prejudice.

Please amend claims 58-72 as follows:

-- 58. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 2 through 50 as described in SEQ ID NO:2. --

-- 59. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 85 through 123 as described in SEQ ID NO:2. --

-- 60. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 46 through 109 as described in SEQ ID NO:2. --

-- 61. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 18 through 98 as described in SEQ ID NO:2. --

-- 62. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 22 through 99 as described in SEQ ID NO:2. --

-- 63. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 21 through 50 as described in SEQ ID NO:2. --

-- 64. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 46 through 85 as described in SEQ ID NO:2. --

-- 65. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 50 through 64 as described in SEQ ID NO:2. --

-- 66. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 67 through 81 as described in SEQ ID NO:2. --

-- 67. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 21 through 99 as described in SEQ ID NO:2. --

-- 68. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 71 through 82 as described in SEQ ID NO:2. --

-- 69. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 85 through 99 as described in SEQ ID NO:2. --

-- 70. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 18 through 50 as described in SEQ ID NO:2. --

-- 71. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 46 through 98 as described in SEQ ID NO:2. --

-- 72. (Amended) The [PSCA protein fragment] method of claim 53, wherein the PSCA protein fragment consists [consisting] of amino acid residues 85 through 98 as described in SEQ ID NO:2. --